Advertisement
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Involvement of an Organic Anion Transporter (Canalicular Multispecific Organic Anion Transporter/Multidrug Resistance-Associated Protein 2) in Gastrointestinal Secretion of Glutathione Conjugates in Rats

Yasumasa Gotoh, Hiroshi Suzuki, Setsuo Kinoshita, Tomoko Hirohashi, Yukio Kato and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics January 2000, 292 (1) 433-439;

Abstract

We investigated the role of cMOAT/MRP2 (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in the intestinal secretion of organic anions by comparing the behavior in Sprague-Dawley (SD) rats and Eisai hyperbilirubinemic rat (EHBR) whose cMOAT/MRP2 is hereditarily defective. After i.v. administration of 1-chloro-2,4-dinitrobenzene (30 μmol/kg), the biliary and intestinal excretion of its glutathione conjugate 2,4-dinitrophenyl-S-glutathione (DNP-SG), a substrate for cMOAT/MRP2, was significantly reduced in EHBR compared with SD rats. This result also was confirmed by Ussing chamber studies; DNP-SG showed 1.5-fold greater serosal-to-mucosal flux compared with the mucosal-to-serosal flux in SD rats, whereas a similar flux was observed in both directions in EHBR. In addition, metabolic inhibitors reduced the preferential serosal-to-mucosal flux of DNP-SG in SD rats. In everted sac studies, intestinal secretion clearance, defined as the efflux rate of DNP-SG into the mucosal side divided by the area under the curve on the serosal side, was significantly lower in the jejunum of EHBR than that in SD rats. Northern blot analyses demonstrated the highest mRNA level of cMOAT/MRP2 in the jejunum, which is in good agreement with the results of the everted sac studies. These results suggest that cMOAT/MRP2 is involved in the secretion of organic anions in the small intestine.

As far as absorption from the small intestine is concerned, extensive studies have been carried out focusing, in particular, on the transporters responsible for uptake across the brush border membrane (Leibach and Ganapathy, 1996; Tsuji and Tamai, 1996). In addition, it has been shown that the gastrointestinal absorption of amphipathic neutral or cationic drugs is prevented by the presence of multidrug resistant (mdr) 1 P-glycoprotein (P-gp), an efflux transporter located on the brush border membrane (for review, see Hunter and Hirst, 1997;Arimori and Nakano, 1998; Wacher et al., 1998). This hypothesis has been confirmed by the finding that the bioavailability of it substrates (such as pacritaxel) in mdr1a and/or mdr1a/1b knockout mice is much higher than that in wild-type mice (Schinkel et al., 1997; Sparreboom et al., 1997). Moreover, in everted sac studies, it has been shown that the P-gp inhibitors and/or antibodies against P-gp increased the serosal flux and decreased the mucosal flux of P-gp substrates such as rhodamine 123 (Hsing et al., 1992), benzopyrene (Penny and Campbell, 1994), digoxin (Su and Huang, 1996), and etoposide (Leu and Huang, 1995). In Ussing chamber studies, the flux of verapamil and propantheline across the rat jejunum was demonstrated to be preferentially directed toward secretion, although some regional differences in secretion were observed (Saitoh and Aungst, 1995).

In addition to P-gp, it is possible that efflux transporter(s) for organic anions are located on the brush border membrane of intestinal cells. This hypothesis is based on findings from Ussing chamber studies that show that the serosal-to-mucosal flux of cefazolin, phenol red, and calcein exceeded the flux in the opposite direction (Saitoh et al. 1996; Fujita et al., 1997). As far as the efflux of organic anions is concerned, it has been established that many organic anions, including the glutathione and glucuronide conjugates of xenobiotics are excreted into the bile via canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2 (cMOAT/MRP2), a primary active-transporter located on the bile canalicular membrane (Oude Elferink et al., 1995; Keppler and König, 1997; Kusuhara et al., 1998; Suzuki and Sugiyama, 1998). The substrate specificity of this transporter has been studied by comparing the transport activity across the bile canalicular membrane of normal rats with transport deficient (TR−) rats or Eisai hyperbilirubinemic rats (EHBR), whose cMOAT/MRP2 is hereditarily defective (Oude Elferink et al., 1995; Keppler and König, 1997; Kusuhara et al., 1998;Suzuki and Sugiyama, 1998). Because cMOAT/MRP2 is expressed in the small intestine of normal rats, but not in mutant rats (Paulusuma et al., 1996; Ito et al., 1997), it is possible that this transporter is responsible for the intestinal excretion of organic anions. Vries et al. (1989) examined this hypothesis using perfused intestine of Wistar and TR− rats. The amount of 1-naphtol-β-d-glucuronide (a cMOAT/MRP2 substrate) excreted into the lumen was almost the same in both strains when the vasculature was perfused with buffer containing 1-naphtol (Vries et al., 1989). This result suggests that cMOAT/MRP2 makes only a minimal contribution to the excretion of this glucuronide in the small intestine (Vries et al., 1989). The purpose of this study is to investigate the role played by cMOAT/MRP2 in the intestinal excretion of glutathione conjugates, typical substrates for this transporter.

Experimental Procedures

Materials.

HPLC grade methanol and acetonitrile were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 1-Chloro-2,4-dinitrobenzene (CDNB), 1-fluoro-2,4-dinitrobenzene (FDNB), reduced glutathione, l-cysteine, andN-acetyl-l-cysteine were purchased from Wako Pure Chemical Industries, Ltd. Cysteinylglycine was purchased from Sigma Chemical Co. (St. Louis, MO). All other chemicals and reagents were commercial products of analytical grade. Male Sprague-Dawley (SD) rats, 7 to 9 weeks old, were purchased from Charles River Japan Inc. (Tokyo, Japan). Male EHBR of the same age, whose cMOAT/MRP2 is hereditarily defective, were kindly provided by Eisai Pharmaceutical Co., Ltd. (Tokyo, Japan). All animals had free access to water and food and the animal experiments were performed according to the guidelines provided by the Institution Animal Care Committee (Graduate School of Pharmaceutical Science, The University of Tokyo).

Chemical Synthesis.

The glutathione-, cysteinylglycine-, cysteine- and N-acetylcysteine-conjugates of FDNB were synthesized with methods reported by Hinchman et al. (1991) (Fig.1). Briefly, 2,4-dinitrophenyl-S-glutathione (DNP-SG), 2,4-dinitrophenyl-S-cysteinylglycine (DNP-CG), and 2,4-dinitrophenyl-N-acetylcysteine (DNP-Nac) were synthesized as follows. FDNB was added slowly to reduced glutathione, cysteinyl glycine, and N-acetylcysteine dissolved in 1 N KHCO3. After incubation for 15 min, the solution was filtered and acidified to ∼pH 2 with diluted HCl. The precipitate was then collected by vacuum filtration. Recrystallization of DNP-SG and DNP-Nac was performed from boiling water, whereas methanol was used for DNP-CG. 2,4-dinitrophenyl-S-cysteine (DNP-Cys) was synthesized by hydrolysis of DNP-Nac with H2SO4 followed by neutralization with NH4OH.

Figure 1
Figure 1

Chemical structure of the glutathione conjugate of CDNB and its subsequent metabolites.

In Vivo Studies.

Intestinal excretion was studied with an in situ single-pass perfusion technique. SD rats and EHBR underwent bile duct cannulation with polyethylene tubing (PE10, i.d. 0.61 mm; Becton Dickinson & Co., Bedford, MA) and were perfused with phosphate-buffered isotonic saline containing 1 mM acivicin, pH 6.0, from the upper duodenum to the end of the ileum with peristaltic pump at a rate of 0.4 ml/min. The body temperature of the rats was maintained under suitable lighting. CDNB (30 μmol/kg), dissolved in middle chain triglyceride, was administered i.v. through the femoral vein and then plasma, bile, and intestinal perfusates were collected at fixed times. Bile specimens and intestinal perfusates were collected at 0 to 30, 30 to 60, 60 to 120, and 120 to 180 min on ice. Blood was collected at 5, 30, 60, 90, and 180 min. Finally, the liver and gastrointestinal tract were removed and all specimens were treated with HClO4 and then subjected to HPLC. CLbile,p and CLperfusate,p were calculated by dividing the cumulative amount excreted into the bile and intestinal perfusate over the 3-h period by the area under the curve (AUC)0–3 h, respectively. To quantitatively express the transport activity across the bile canalicular membrane of hepatocytes and the brush border membrane of enterocytes, we determined CLbile,liver and CLperfusate,intestine, respectively. These are defined as the cumulative amount excreted into the bile and intestinal perfusate between 2 and 3 h after initiation of experiments by the liver or the intestine concentration at the end of experiment (3 h), respectively.

Everted Sacs and Ussing Chamber Studies.

SD rats and EHBR were anesthetized with ether and were sacrificed by exsanguination from the abdominal aorta. Then, the duodenum, jejunum, ileum, and colon were immediately removed and rinsed in ice-cold saline. Two- and 3-cm segments of intestine were isolated to perform Ussing chamber and everted sac studies, respectively. These tissues were pretreated with ice-cold Krebs' phosphate buffer, pH 6.0, containing 40 mM glucose and 1 mM acivicin to inhibit γ-glutamyl transferase. Peyer's patches were identified visually, and sections of tissue containing them were not used. For the everted sac studies, the intestinal segments were slid onto a piston and the epithelial surface exposed. These everted segments were ligated at both ends, and pretreated with 2 ml Krebs' phosphate buffer, pH 6.0, containing 40 mM glucose and 1 mM acivicin for 20 min to completely inhibit the γ-glutamyltransferase, and then they were filled with 200 ml of DNP-SG dissolved in buffer. The solution was gassed with O2/CO2 (95:5) at 37°C. Aliquots from inside the sacs (20 ml) and samples from outside the sacs (200 μl) were collected at 0, 20, and 60 min by microsyringe. Finally, the sac was washed with drug-free buffer and homogenized. All specimens were treated with HClO4 and then subjected to HPLC. The results are expressed as net clearance, which were obtained by dividing the cumulative amount of DNP-SG excreted into the mucosal side by the AUC on the serosal side, and tissue clearance, which were obtained by dividing the cumulative amount of DNP-SG excreted into the mucosal side by the intestinal tissue concentration during the final period.

For Ussing chamber studies, the intestinal segments were mounted in a diffusion cell. To both compartments were added 3 ml of Krebs' phosphate buffer, pH 6.0, containing 40 mM glucose and 1 mM acivicin, prewarmed to 37°C for 20 min. Subsequently, the same buffer containing DNP-SG was added to the donor compartment, and the same volume of drug-free buffer was added to the receiving compartment. Aliquots (1 μl) from the receiving chamber were taken at designated times and replaced with the same volume of drug-free buffer. All specimens were treated with HClO4 and then subjected to HPLC. The exposed intestinal surface area was 0.635 cm2. The results are expressed as clearance values, obtained by dividing the flux by the initial donor concentration. All results are expressed as means ± S.E. Statistical comparisons were made with Student's t tests.

HPLC Analysis.

The HPLC system consisted of a Hitachi model 6000 series liquid chromatograph. Isocratic elution was performed with a Bakerbond NP Octadecyl C18 column (4.6 × 250 mm, 5 μm; J.T. Baker Research Products, Phillipsburg, NJ) with a mobile phase of acetonitrile: 0.01% H3PO4(1:3, v/v) at a flow rate of 1.0 ml/min (Hinchman et al., 1991). Compounds were detected at 365 nm and quantified by the external standard method by the height of the peaks. Retention times for DNP-SG, DNP-CG, DNP-Cys, and DNP-Nac were about 10, 24, 7, and 12 min, respectively.

Northern Hybridization.

Northern hybridization was performed as described previously (Ito et al., 1996, 1997). The mRNA was prepared from liver, duodenum, jejunum, ileum, and colon dissected from three SD rats. As a probe for the hybridization, full-length cMOAT/MRP2 was used. 32P labeled cDNA for glyceraldehyde 3-phosphate dehydrogenase (G3PDH; Clontech Laboratories, Palo Alto, CA) was used to normalize the amount of mRNA. Two micrograms of mRNA was applied to the gel. The intensity of specific bands was quantified from a standard curve with a BAS 2000 system (Fuji Photo Film Co., Ltd., Tokyo, Japan).

Results

In Vivo Studies.

Plasma concentration-time profiles of CDNB conjugates after i.v. administration of CDNB (30 μmol/kg) are shown in Fig. 2. Plasma profiles of CDNB metabolites were comparable between SD rats and EHBR (Fig. 2). In both rat strains, the highest plasma level of DNP-SG, followed by DNP-Nac was observed (Fig. 2). Plasma concentrations of DNP-CG and DNP-Cys were much lower than that of DNP-SG and DNP-Nac in both rat strains (Fig.2). In SD rats, DNP-SG and DNP-Nac were the main metabolites detected in the bile, whereas the biliary excretion of these conjugates was markedly reduced in EHBR (Fig. 2). The amount of DNP-CG and DNP-Cys excreted into the bile was much lower than that of DNP-SG and DNP-Nac in both SD rats and EHBR. As shown in Table1, the CLbile,p and CLbile,liver values of DNP-SG in SD rats were 1.16 μl/min/kg and 7.71 ml/min/kg, respectively, and these were significantly higher than the corresponding values in EHBR (0.11 μl/min/kg and 2.21 ml/min/kg, respectively).

Figure 2
Figure 2

Time profiles for plasma concentration and cumulative biliary excretion of DNP-SG and its subsequent metabolites. SD rats and EHBR received i.v. injection of CDNB (30 μmol/kg) to examine the plasma concentration (top) and biliary excretion (bottom) of its metabolites. Each point and vertical bar represents the mean ± S.E. of five rats. ●, DNP-SG; ▴, DNP-CG; ■, DNP-Cys; ×, DNP-Nac.

View this table:
Table 1

Kinetic parameters of DNP-SG and its subsequent metabolites after i.v. administration of CDNB (30 μmol/kg) to SD rats and EHBR

After i.v. administration of CDNB, small intestinal excretion of DNP-SG, DNP-Cys, and DNP-Nac was observed in SD rats, whereas the secretion of DNP-SG and DNP-Nac was markedly reduced in EHBR (Fig.3). In addition, the calculated CLperfusate,p and CLperfusate,intestine values of DNP-SG in SD rats were 69.3 nl/min/kg and 0.11 ml/min/kg, respectively, whereas there was a reduction in the corresponding values for EHBR (13.6 nl/ml/min/kg and 0 ml/min/kg, respectively) (Table 1). DNP-CG was not detectable in both strains.

Figure 3
Figure 3

Cumulative intestinal excretion of DNP-SG and its subsequent metabolites. SD rats and EHBR received i.v. injection of CDNB (30 μmol/kg) to examine the intestinal excretion of DNP-SG and its subsequent metabolites. The plasma concentration and biliary excretion of a series of CDNB metabolites are shown in Fig. 2. Each point and vertical bar represents the mean ± S.E. of five rats. ●, DNP-SG; ▴, DNP-CG; ■, DNP-Cys; ×, DNP-Nac.

Everted Sac and Ussing Chamber Studies.

The efflux of DNP-SG in duodenum, jejunum, ileum, and colon from SD rats and EHBR was compared in everted sac studies (Fig. 4). The net clearance, along with tissue clearance, in SD rats jejunum was higher than that in EHBR (Fig. 4). Thus, we have examined the following to gain insight into the intestinal secretion mechanism of DNP-SG with an Ussing-type chamber. In an in vitro comparison with an Ussing chamber, the intestinal permeability was compared between the mucosal-to-serosal and serosal-to-mucosal directions in SD rats and EHBR. Time profiles for the trans-epithelial transport of DNP-SG across jejunum are shown in Fig.5. DNP-SG showed greater permeation in the serosal-to-mucosal direction than in the mucosal-to-serosal direction in SD rats, whereas little difference was observed between the two directions in EHBR (Fig. 5). The preferential serosal-to-mucosal transport of DNP-SG was reduced in the presence of metabolic inhibitors (Fig. 6).

Figure 4
Figure 4

Intestinal excretion clearance of DNP-SG in the everted sac study. The everted sac segments from duodenum, jejunum, ileum, and colon were used to examine the export of DNP-SG. Everted sacs were filled with Krebs' phosphate buffer containing DNP-SG (118 μM) and acivicin (1 mM) to examine the export of this conjugate into the medium bathing the sacs. The results are given as net clearance (top), which were obtained by dividing the cumulative amount of DNP-SG in the bathing medium by the AUC in the sacs, and as tissue clearance (bottom), which were obtained by dividing the efflux rate of DNP-SG into the bathing medium by the intestinal tissue concentration at the end of the experiments. Statistical comparisons were made with Student's t tests. Each value and vertical bar represents the mean ± S.E. of six independent experiments. ▪, SD rats; ■, EHBR.

Figure 5
Figure 5

Intestinal excretion of DNP-SG in the Ussing chamber study. Time profiles for the mucosal-to-serosal and serosal-to-mucosal flux of DNP-SG in the jejunum of SD rats and EHBR were examined (left). The studies were performed at 37°C in Krebs' phosphate buffer containing 1 mM acivicin. Experiments were initiated by added DNP-SG (95.8 μM) to the donor compartment. The bar graph represents the permeability clearance, which was obtained by dividing the flux by the initial donor concentration. Statistical comparisons were performed with Student's t tests. Results are shown as the mean ± S.E. of three rats. Squares, mucosal-to-serosal flux; triangles, serosal-to-mucosal flux; open symbols and bars, EHBR; closed symbols and bars, SD rats.

Figure 6
Figure 6

Effect of metabolic inhibitors in the transcellular transport of DNP-SG across SD rat jejunum. Transcellular transport of DNP-SG across the jejunum of SD rats was investigated with an Ussing chamber. The experimental conditions are the same as that described for Fig. 5, except that metabolic inhibitors (25 mM 3-O-methylglucose, 10 mM NaF, 10 mM NaN3) were added to both compartments. The results of the control experiments were taken from Fig. 5. Statistical comparisons were performed with Student's t tests. Each value and vertical bar represents the mean ± S.E. of three rats. ■, control experiments; ▪, in the presence of metabolic inhibitors.

The mRNA level of cMOAT/MRP2 in the small intestine of SD rats was examined by Northern blot analysis. Figure7 shows the ratio of cMOAT/MRP2 to G3PDH in the duodenum, jejunum, ileum, and colon of SD rats. The mRNA level of cMOAT/MRP2 in the duodenum and jejunum was higher than in the ileum or colon (Fig. 7).

Figure 7
Figure 7

Expression of cMOAT/MRP2. The mRNA levels for cMOAT/MRP2 were determined in duodenum, jejunum, ileum, and colon in SD rats. The expression of cMOAT/MRP2 was normalized by that of G3PDH. Statistical comparisons were performed with Student'st tests. Each value and vertical bar represents the mean ± S.E. of three independent experiments.

Discussion

The previous results of Northern blot analysis indicated the significant expression of cMOAT/MRP2 in the small intestine of SD rats (Paulusma et al., 1996; Ito et al., 1997). In addition, RT-PCR analysis indicated the introduction of a premature stop codon in the open reading frame of cMOAT/MRP2 cDNA prepared from the small intestine of EHBR (Ito et al., 1997). These results show that a comparison between SD rats and EHBR provides us information on the functional significance of cMOAT/MRP2 in this epithelial tissue. In the present study, we investigated the contribution of cMOAT/MRP2 in the small intestinal excretion of a glutathione conjugate (DNP-SG) and its subsequent metabolites (DNP-CG, DNP-Cys, and DNP-Nac) with these two rat strains. By examining the transport across the bile canalicular membrane, it has been demonstrated that leukotriene C4(LTC4) and its metabolites [leukotriene D4, leukotriene E4 andN-acetyl leukotriene E4(NAcLTE4)] are substrates for cMOAT/MRP2 (Huber et al., 1987; Ishikawa et al., 1990).

At first, the intestinal excretion of the glutathione conjugate of CDNB and its subsequent metabolites was examined in relation to the biliary excretion in in vivo experiments. After i.v. administration of CDNB to SD rats and EHBR, DNP-SG, along with DNP-Nac, were the main biliary metabolites in SD rats and the excretion of these metabolites was significantly reduced in EHBR (Fig. 2). In contrast, the plasma profile of DNP-SG after i.v. administration of CDNB (30 μmol/kg) was similar in SD rats and EHBR (Fig. 2). These results can be accounted for by considering the fact that the amount of DNP-SG excreted into the bile and intestinal lumen was only 8.7 and 0.87% of the administered dose in SD rats and EHBR, respectively (Fig. 2; Table 1). Although we have not determined the urinary excretion of DNP-SG, it is possible that this excretion pathway plays a predominant role in the elimination of DNP-SG from plasma in both SD rats and EHBR.

Thus, we were able to confirm the marked reduction in the biliary excretion of glutathione conjugates and end products of mercapturic acid pathway in cMOAT/MRP2-deficient animals (Huber et al., 1987). Previously, Huber et al. (1987) demonstrated that [3H]NAcLTE4 (an end product of the mercapturic acid pathway) was predominantly excreted into the bile after i.v. injection of [3H]LTC4 (a glutathione conjugate). Moreover, they indicated that [3H]NAcLTE4 is transported by cMOAT/MRP2, with isolated bile canalicular membrane vesicles (Huber et al., 1987). In contrast, it was revealed that DNP-Nac is not necessarily a good substrate for cMOAT/MRP2; we examined the inhibitory effect of DNP-Nac on cMOAT/MRP2-mediated transport of [3H]DNP-SG in isolated bile canalicular membrane vesicles. The IC50 value of DNP-Nac was >1 mM, which was much higher than theKm value of DNP-SG (16.5 + 2.4 μM). Therefore, it is plausible that DNP-SG, after being excreted into the bile and intestinal lumen, is metabolized to DNP-Nac. The reduced excretion of DNP-Nac in EHBR may result from the reduced excretion of DNP-SG in this mutant rat strain.

With regard to the intestinal secretion, the excretion of DNP-SG was markedly reduced in EHBR (Fig. 3), suggesting that the intestinal secretion of this conjugate is largely mediated by cMOAT/MRP2. This result was further confirmed by everted sac studies in which a reduction in intestinal secretion clearance was observed in EHBR compared with SD rats (Fig. 4). In particular, DNP-SG efflux from the jejunum of EHBR was significantly reduced compared with that in SD rats (Fig. 4). Because we found no difference in the net and tissue clearances of vinblastine (1 μM) between SD rats and EHBR (data not shown), the suitability of this experimental system was confirmed. Northern blot analyses demonstrated the highest mRNA level of cMOAT/MRP2 in the jejunum, which is in good agreement with the results from the everted sac studies (Fig. 7).

Moreover, in the Ussing chamber studies, DNP-SG exhibited a 1.5-fold greater flux in the serosal-to-mucosal direction than in the mucosal-to-serosal direction in SD rats, whereas no significant difference was observed between these two directions in EHBR (Fig. 5). Because metabolic inhibitors reduced the preferential serosal-to-mucosal flux of DNP-SG in SD rats (Fig. 6), it was suggested that the net apical secretion of DNP-SG across the rat jejunum is mediated by cMOAT/MRP2.

However, the difference in the flux of DNP-SG between SD rats and EHBR in vitro (Figs. 4 and 5) was smaller than that observed in vivo (Fig.3). These results may be ascribed to the difference in the concentration of DNP-SG. In our in vitro experiments, we used the minimal concentration of DNP-SG that could be detected by HPLC. Although the medium concentration of DNP-SG was ∼100 μM, the concentration of this compound in the intestinal tissue in in vitro experiments was found to be 15 nmol/g tissue (∼15 μM). Because the unbound concentration of DNP-SG in the tissue should be lower than itsKm value for cMOAT/MRP2 (∼20 μM), cMOAT/MRP2 function would be detectable in our in vitro experiments. However, these concentrations were higher than those observed in in vivo experiments (<25 μM; Fig. 2).

Collectively, these results indicate that cMOAT/MRP2, located on the brush border membrane of enterocytes, plays a significant role in the secretory function of glutathione conjugates. The apical localization of cMOAT/MRP2 in the epithelial cells is in good agreement with the fact that this transporter is located on the bile canalicular (apical) membrane of hepatocytes (Büchler et al., 1996; Paulusma et al., 1996). In addition, with antibody against cMOAT/MRP2, Schaub et al. (1997) demonstrated the apical localization of this protein in renal tubular cells. Transfection of rat and human cMOAT/MRP2 cDNA results in the apical expression of cDNA products in MDCK cells (Evers et al., 1998; Kinoshita et al., 1998). Although we have tried to determine the localization of cMOAT/MRP2 in small intestine with the immunohistochemical techniques, it was difficult to clearly demonstrate its apical localization. Because our preliminary experiments indicated that it is easier for us to perform the immunochemical studies in human tissues than rat tissues, we used human specimens. We prepared antiserum against a C-terminal peptide sequence of human cMOAT/MRP2, as described in a previous report (Kartenbeck et al., 1996); Keppler and his collaborators have prepared the antiserum against this peptide (EAG 5) and have used it for the immunohistochemical staining of human liver (Kartenbeck et al., 1996). Although we found that the bile canalicular membrane of human liver is indeed stained with this antiserum (unpublished data) as reported previously (Kartenbeck et al., 1996), the signal for the staining was very weak in the human small intestine. Minimal staining of the small intestine is consistent with our previous observation that the expression level of cMOAT/MRP2 is much weaker in the small intestine compared with the liver (Ito et al., 1997).

In both everted sac and Ussing chamber studies, we found a significant flux of DNP-SG even in EHBR (Figs. 4 and 5). In particular, in the Ussing chamber studies, we found a symmetrical flux of this glutathione conjugate in EHBR (Fig. 5). These results may be accounted for by the hypothesis that other transporters located on both brush border and basolateral membranes are responsible for the excretion of DNP-SG, even in EHBR, although we cannot exclude the possibility that passive diffusion mediates the symmetrical excretion.

Finally, the discrepancy between the results of the present study and those of Vries et al. (1989) needs to be discussed. Vries et al. (1989)found that the small intestinal excretion of 1-naphtol-β-d-glucuronide into both the mucosal and serosal sides is similar in both TR− and Wistar rats after preloading its precursor (1-naphtol) from the serosal side. It is possible that transporter(s) that preferentially accept glucuronide conjugates, rather than glutathione conjugates, may be expressed on the small intestinal brush border membrane of both EHBR and SD rats at a comparable level and, therefore, the contribution of cMOAT/MRP2 to the excretion of glucuronides were poor substrates for this transporter (Hirohashi et al., 1999). However, it has been recently demonstrated that MRP3 is located on the basolateral membrane in both hepatocytes (König et al., 1999; Kool et al., 1999) and enterocytes (K. Oda, J. Shoda, T.H., H.S., and Y.S., unpublished observations). Such a substrate-dependent differential contribution of cMOAT/MRP2 to epithelial excretion was recently demonstrated with respect to the renal excretion of fluorescent dyes (Russel et al., 1999). Russel et al. (1999) found that the urinary excretion of calcein, but not lucifer yellow, was impaired in TR−.

In conclusion, the results of the present study suggest that cMOAT/MRP2 plays an important role in the small intestinal excretion of glutathione conjugates. Although the mucosal efflux of several organic anions (such as cefazolin, phenol red, and calcein) has been previously reported (Saitoh et al., 1996; Fujita et al., 1997), and some of them have been identified as substrates for MRP family, the contribution of cMOAT/MRP2 to the excretion of these ligands remains to be clarified.

Footnotes

  • Send reprint requests to: Dr. Yuichi Sugiyama, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail:sugiyama{at}seizai.f.u-tokyo.ac.jp

  • Abbreviations:
    mdr
    multidrug resistant
    P-gp
    P-glycoprotein
    cMOAT
    canalicular multispecific organic anion transporter
    MRP
    multidrug resistance-associated protein
    TR−
    transport deficient rats
    EHBR
    Eisai hyperbilirubinemic rats
    CDNB
    1-chloro-2,4-dinitrobenzene
    FDNB
    1-fluoro-2,4-dinitrobenzene
    SD rats
    Sprague-Dawley rats
    DNP-SG
    2,4-dinitrophenyl-S-glutathione
    DNP-CG
    2,4-dinitrophenyl-S-cysteinylglycine
    DNP-Nac
    2,4-dinitrophenyl-N-acetylcysteine
    DNP-Cys
    2,4-dinitrophenyl-S-cysteine
    AUC
    area under the curve
    G3PDH
    glyceraldehyde 3-phosphate dehydrogenase
    LTC4
    leukotriene C4
    NAcLTE4
    N-acetyl leukotriene E4
    • Received June 14, 1999.
    • Accepted October 4, 1999.

References

  1. ↵
    1. Arimori K,
    2. Nakano M
    (1998) Drug exsorption from blood into the gastrointestinal tract. Pharm Res 15:371–376.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Büchler M,
    2. König J,
    3. Brom M,
    4. Kartenbeck J,
    5. Spring H,
    6. Horie T,
    7. Keppler D
    (1996) cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 271:15091–15098.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Evers R,
    2. Kool M,
    3. van Deemter L,
    4. Janssen H,
    5. Calafat J,
    6. Oomen LC,
    7. Paulusma CC,
    8. Oude Elferink RP,
    9. Bass F,
    10. Schinkel AH,
    11. Borst P
    (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101:1310–1319.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Fujita T,
    2. Yamada H,
    3. Fukuzumi M,
    4. Nishimaki A.,
    5. Yamamoto A,
    6. Muranishi S
    (1997) Calcein is excreted from the intestinal mucosal cell membrane by the active transport system. Life Sci 60:307–313.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Hinchman CA,
    2. Matsumoto H,
    3. Simmons TW,
    4. Ballatori N
    (1991) Intrahepatic conversion of a glutathione conjugate to its mercapturic acid. Am Soc Biochem Mol Biol 266:22179–22185.
    OpenUrl
  6. ↵
    1. Hirohashi T,
    2. Suzuki H,
    3. Sugiyama Y
    (1999) Characterization of the transport properties of cloned rat multidrug resistance associated protein 3 (MRP3). J Biol Chem 274:15181–15185.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Hsing S,
    2. Gatmaitan Z,
    3. Arias IM
    (1992) The function of gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 102:879–885.
    OpenUrlPubMed
  8. ↵
    1. Huber M,
    2. Guhlmann A,
    3. Jansen PL,
    4. Keppler D
    (1987) Hereditary defect of hepatobiliary cysteinyl leukotriene elimination in mutant rats with defective hepatic anion excretion. Hepatology 7:224–228.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Hunter J,
    2. Hirst BH
    (1997) Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 25:129–157.
    OpenUrlCrossRef
  10. ↵
    1. Ishikawa T,
    2. Muller M,
    3. Klunemann C,
    4. Schaub T,
    5. Keppler D
    (1990) ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem 265:19279–19286.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Ito K,
    2. Suzuki H,
    3. Hirohashi T,
    4. Kume K,
    5. Shimizu T,
    6. Sugiyama Y
    (1996) Expression of the putative ATP-binding cassette region, homologous to that in multidrug resistance associated protein (MRP), is hereditarily defective in Eisai hyperbirilubinemic rats (EHBR). Int Hepatol Commun 4:292–299.
    OpenUrl
  12. ↵
    1. Ito K,
    2. Suzuki H,
    3. Hirohashi T,
    4. Kume K,
    5. Shimizu T,
    6. Sugiyama Y
    (1997) Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Physiol 272:G16–G22.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Kartenbeck J,
    2. Leuschner U,
    3. Mayer R,
    4. Keppler D
    (1996) Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23:1061–1066.
    OpenUrlPubMed
  14. ↵
    1. Keppler D,
    2. König J
    (1997) Hepatic canalicular membrane 5: Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J 11:509–516.
    OpenUrlAbstract
  15. ↵
    1. Kinoshita S,
    2. Suzuki H,
    3. Ito K,
    4. Kume K,
    5. Shimizu T,
    6. Sugiyama Y
    (1998) Transfected rat cMOAT is functionally expressed on the apical membrane in Madin-Darby canine kidney (MDCK) cells. Pharm Res 15:1851–1856.
    OpenUrlCrossRefPubMed
  16. ↵
    1. König J,
    2. Rost D,
    3. Cui Y,
    4. Keppler D
    (1999) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29:1156–1163.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Kool M,
    2. Linden M,
    3. Haas M,
    4. Scheffer GL,
    5. Vree JML,
    6. Smith AJ,
    7. Jansen G,
    8. Peters GJ,
    9. Ponne N,
    10. Scheper RJ,
    11. Oude Elferink RP,
    12. Baas F,
    13. Borst P
    (1999) MRP3, an organic anion transporter able to transport anti-cancer drug. Proc Natl Acad Sci USA 96:6914–6919.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Kusuhara H,
    2. Suzuki H,
    3. Sugiyama Y
    (1998) The role of P-glycoprotein and canalicular multispecific organic anion transporter (cMOAT) in the hepatobiliary excretion of drugs. J Pharm Sci 87:1025–1040.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Leibach FH,
    2. Ganapathy V
    (1996) Peptide transporters in the intestine and the kidney. Ann Rev Nutrit 16:99–119.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Leu BL,
    2. Huang JD
    (1995) Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35:432–436.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Oude Elferink RP,
    2. Meijer DK,
    3. Kuipers F,
    4. Jansen PL,
    5. Groen AK,
    6. Groothuis GM
    (1995) Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim Biophys Acta 1241:215–268.
    OpenUrlPubMed
  22. ↵
    1. Paulusma CC,
    2. Bosma PJ,
    3. Zaman GJ,
    4. Bakker CT,
    5. Otter M,
    6. Scheffer GL,
    7. Scheper RJ,
    8. Borst P,
    9. Oude Elferink RP
    (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (Wash DC) 271:1126–1128.
    OpenUrlAbstract
  23. ↵
    1. Penny JI,
    2. Campbell FC
    (1994) Active transport of benzo[a]pyrene in apical membrane vesicles from normal human intestinal epitherium. Biochem Biophys Acta 1226:232–236.
    OpenUrlPubMed
  24. ↵
    1. Russel FGM,
    2. van Aubel RAMH,
    3. Masereeuw R
    (1999) Role and substrate specificity of Mrp2 in the renal excretion of anionic xenobiotics and conjugates. Abstract of 2nd FEBS Advanced Lecture Course, “ATP-binding cassette transporters: From multidrug resistance to genetic disease.”.
  25. ↵
    1. Saitoh S,
    2. Aungst BJ
    (1995) Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res 12:1304–1310.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Saitoh S,
    2. Gerard C,
    3. Aungst BJ
    (1996) The secretory intestinal transport of some beta-lactam antibiotics and anionic compounds: a mechanism contributing to poor oral absorption. J Pharmacol Exp Ther 278:205–211.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Schaub TP,
    2. Kartenbeck J,
    3. König J,
    4. Vogel O,
    5. Witzgall R,
    6. Kriz W,
    7. Keppler D
    (1997) Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 8:1213–1221.
    OpenUrlAbstract
  28. ↵
    1. Schinkel AH,
    2. Mayer U,
    3. Wagenaar E.,
    4. Mol CAAM,
    5. van Deemter L,
    6. Smit JJM,
    7. van der Valk MA,
    8. Voordouw AC,
    9. Spits H,
    10. van Tellingen O,
    11. Zijlmans JMJM,
    12. Fibbe WE,
    13. Borst P
    (1997) Normal viability and altered pharmacokinetis in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028–4033.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Sparreboom A,
    2. Asperen JV,
    3. Mayer U,
    4. Schinkel AH,
    5. Smit JW,
    6. Meijer DKF,
    7. Borst P,
    8. Nooijen WJ.,
    9. Beijnen JH,
    10. Tellingen OV
    (1997) Limited oral bioavailability and active epitherial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestione. Pharmacology 94:2031–2035.
    OpenUrl
  30. ↵
    1. Su SF,
    2. Huang JD
    (1996) Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 24:142–147.
    OpenUrlAbstract
  31. ↵
    1. Suzuki H,
    2. Sugiyama Y
    (1998) Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin Liver Dis 18:359–376.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Tsuji A,
    2. Tamai I
    (1996) Carrier-mediated intestinal transport of drugs. Pharm Res 13:963–977.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Vries MH,
    2. Redegeld FA,
    3. Koster AS,
    4. Noordhoek J,
    5. Haan JG,
    6. Oude Elferink RPJ
    (1989) Hepatic, intestinal and renal transport of 1-naphthol-beta-d-glucuronide in mutant rats with hereditary-conjugated hyperbilirubinemia. Naunyn-Schmiedeberg's Arch Pharmacol 340:588–592.
    OpenUrlPubMed
  34. ↵
    1. Wacher VJ,
    2. Silverman JA,
    3. Zhang Y,
    4. Benet LZ
    (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322–1330.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Involvement of an Organic Anion Transporter (Canalicular Multispecific Organic Anion Transporter/Multidrug Resistance-Associated Protein 2) in Gastrointestinal Secretion of Glutathione Conjugates in Rats

Yasumasa Gotoh, Hiroshi Suzuki, Setsuo Kinoshita, Tomoko Hirohashi, Yukio Kato and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics January 1, 2000, 292 (1) 433-439;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section